Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer’s disease models

Highlights • Pre-plaque changes of systemic inflammatory markers. • Early communication between brain and blood immunity. • TKIs in early pre-plaque Aβ stages modulate systemic and brain immunity. • TKIs synchronize peripheral and CNS immune responses in early disease stages. • TKIs may be used in t...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience 2015-09, Vol.304, p.316-327
Main Authors: Lonskaya, I, Hebron, M.L, Selby, S.T, Turner, R.S, Moussa, C.E.-H
Format: Article
Language:English
Subjects:
Aging - drug effects
Aging - pathology
Aging - physiology
Amyloid beta-Peptides - metabolism
Amyloid beta-Protein Precursor - genetics
Amyloid beta-Protein Precursor - metabolism
Aniline Compounds - pharmacology
Animals
Astrocytes - pathology
Astrocytes - physiology
bosutinib
Brain - drug effects
Brain - pathology
Brain - physiopathology
CX3CL1
Cytokines - metabolism
Disease Models, Animal
Enzyme Inhibitors - pharmacology
Female
Humans
inflammation
Intracellular Space - drug effects
Intracellular Space - metabolism
Male
Mice, Inbred C57BL
Mice, Transgenic
Microglia - pathology
Microglia - physiology
Neuroimmunomodulation - drug effects
Neuroimmunomodulation - physiology
Neurology
nilotinib
Nitriles - pharmacology
Peptide Fragments - metabolism
plaque
Plaque, Amyloid - drug therapy
Plaque, Amyloid - pathology
Plaque, Amyloid - physiopathology
Protein-Tyrosine Kinases - antagonists & inhibitors
Protein-Tyrosine Kinases - metabolism
Pyrimidines - pharmacology
Quinolines - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Pre-plaque changes of systemic inflammatory markers. • Early communication between brain and blood immunity. • TKIs in early pre-plaque Aβ stages modulate systemic and brain immunity. • TKIs synchronize peripheral and CNS immune responses in early disease stages. • TKIs may be used in the treatment of early AD.
ISSN:0306-4522
1873-7544
DOI:10.1016/j.neuroscience.2015.07.070